NCT07272460Recruiting
Time Restricted-EAting for Type 2 Diabetes and MEtabolic Health: the TEA TIME Trial
Time Restricted-eating and Metabolic Health in Patients With Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 11 Feb 2026
Brief summary (registry, in English)
Time-restricted eating - where no food is consumed over a period of time - has been shown to promote weight loss and improve cardio-metabolic function. In individuals with type 2 diabetes, it is also been shown to improve glucose control. The investigators propose a randomized controlled trial to determine whether time-restricted eating is an effective therapeutic strategy that can preserve pancreatic beta-cell function and improve glycemic control early in participants with type 2 diabetes.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 112 (estimated)
- First submitted
- 29 Sept 2025
- Start date
- 1 Feb 2026
- Primary completion date
- 30 Mar 2029
- Lead sponsor
- Mount Sinai Hospital, Canada
- Diseases
- Type 2 diabetes
- NCT number
- NCT07272460
What you commit to
- Study type: Interventional
- Planned participants: 112
- From 1 Feb 2026 to the primary completion date, 30 Mar 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current diabetes treatment with insulin, glucagon-like peptide-1 receptor agonists, and/or sulfonylureas.
- Previous surgical treatment for weight loss such as gastric bypass or gastric band
- Malignant neoplasm requiring chemotherapy, surgery, radiation or palliative therapy within the previous 5 years (with the exception of basal cell skin cancer)
- Concurrent participation in another research study relevant to diabetes and metabolic health
Other illness
- Any history of eating disorder
- New York Heart Association class II-IV heart failure
Lab values
- Renal dysfunction as evidenced by estimated glomerular filtration rate \< 25 ml/min by CKD-EPI Creatinine Equation
- Hepatic disease considered to be clinically significant (includes jaundice, chronic hepatitis, or previous liver transplant) or transaminases \>2.5X the upper limit of normal
Other
- Use of any other pharmacological treatment for weight-loss
- Currently pregnant or lactating
- Any other factor likely to limit adherence to the study, in the opinion of the investigators
Who the study is looking for
- Individuals with previously diagnosed BMI ≥ 25 kg/m2 and type 2 diabetes within preceding 10 years.
- Age 18 - 75 years inclusive
- Stable weight over past 12 weeks (less than 5% change in body weight) (self-reported)
- Diabetes treatment consisting of lifestyle only or metformin, dipeptidyl peptidase-4 (DPP-4) inhibitor, and sodium-glucose co-transporter 2 (SGLT2) inhibitors either as monotherapy or in combination.
- Ability to read and understand English
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Leadership Sinai Centre for Diabetes Coordinator of this site? Confirm its status | Toronto | Canada | Recruiting |
Related publications
- Time restricted EAting for Type 2 diabetes and MEtabolic health: The TEA TIME trial study protocol.PLoS One · 2026 · PMID 41818195
This page is information, not medical advice. Discuss any trial with your doctor.